Enanta制药 ENTA 深 沪
等待开盘 07-01 09:30:00 美东时间
14.58
+0.070
+0.48%
华盛通- 最 高14.665
- 今 开14.53
- 成交量 28.12万股
- 最 低 14.255
- 昨 收 14.51
- 总市值 42.40万
- 52周最高 17.15
- 市盈率 静 --
- 换手率 0.97%
- 52周最低 6.435
- 委 比 43.55%
- 总股本 2.91万
- 历史最高 127.77
- 量 比 0.65
- 振 幅 2.83%
- 历史最低 4.09
- 每 手 1
- 风险率 2.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 美银上调美光科技目标价从950美元升至1500美元，上调迈威尔科技目标价从240美元升至365美元
今日重点评级关注：摩根士丹利：维持杜邦"标配"评级，目标价从52美元升至156美元；蒙特利尔银行：维持Taysha Gene Therapies"跑赢大市"评级，目标价从10美元升至14美元
06-24 14:08
Enanta Faces Patent Setback in Paxlovid Litigation
The latest announcement is out from Enanta Pharmaceuticals ( ($ENTA) ). Enanta ...
06-24 06:43
AbbVie, Enanta announce EU label expansion for hepatitis C therapy, Maviret
AbbVie (ABBV) and Enanta Pharmaceuticals (ENTA) announced on Tuesday that the European Commission has approved a label expansion for their jointly developed hepatitis C therapy, Maviret. Accordingly, ...
06-23 19:34
EU approves AbbVie’s Mavyret, discovered by Enanta, for acute hepatitis C treatment
EU approves AbbVie’s Mavyret, discovered by Enanta, for acute hepatitis C treatment European Commission cleared AbbVie’s Maviret (glecaprevir/pibrentasvir) to treat acute hepatitis C in adults and children aged 3+ in the EU. The label expansion makes Maviret the only EU-approved therapy for both acu
06-23 17:10
Enanta Pharma Advances Zelicapavir Into Registrational Phase 2b/3 Clinical Trial In Adults At High Risk Of Severe Outcomes From RSV Infection After End-Of-Phase 2 Meeting With FDA
Registrational Ph2b/3 Trial of Zelicapavir to Initiate in High-Risk Adults with RSV in 4Q 2026, with Topline Phase 2b Data Expected in 2027 Phase 2b Trial of Zelicapavir to Initiate in Pediatric Patients with RSV in 3Q 2026, with Topline Data Expected in 2027 Enanta Pharmaceuticals, Inc. (NASDAQ:ENT...
06-18 19:06
Enanta将出席Jefferies全球医疗大会 聚焦RSV与免疫管线进展
Enanta Pharmaceuticals周四宣布，公司将出席即将举行的Jefferies全球医疗大会，与投资者分享其在呼吸道合胞病毒治疗和免疫学领域的最...
05-28 23:17
European Medicines Agency Announces Meeting highlights From The Committee For Medicinal Products for Human Use, May 18-21
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-18-21-may-2026
05-22 18:59
Enanta Pharma shares are trading lower. The company reported Q2 financial results.
Enanta Pharma shares are trading lower. The company reported Q2 financial resul...
05-13 00:43
Enanta Pharmaceuticals To Highlight Pipeline Progress With Oral Presentation And Asthma Drug Posters
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the Company will have an
05-04 19:13
Enanta Pharmaceuticals appeal oral argument set for May 11, 2026; litigation targets Pfizer over Paxlovid patent infringement
Enanta Pharmaceuticals appeal oral argument set for May 11, 2026; litigation targets Pfizer over Paxlovid patent infringement Enanta is appealing a Federal Circuit case against Pfizer seeking damages for alleged infringement of U.S. Patent No. 11,358,953 related to Paxlovid. Oral argument in the app
03-26 20:02
